Agios Pharmaceuticals, Inc. (AGIO) Issues Earnings Results
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its earnings results on Wednesday. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19, Bloomberg Earnings reports. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. During the same quarter in the previous year, the firm posted ($1.63) EPS. The firm’s revenue was up 26.4% on a year-over-year basis.
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 2.295% on Wednesday, hitting $62.795. 414,380 shares of the company were exchanged. The company’s market capitalization is $3.04 billion. Agios Pharmaceuticals has a 52 week low of $39.24 and a 52 week high of $72.73. The firm’s 50 day moving average is $67.72 and its 200 day moving average is $57.76.
COPYRIGHT VIOLATION NOTICE: “Agios Pharmaceuticals, Inc. (AGIO) Issues Earnings Results” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/01/agios-pharmaceuticals-inc-agio-issues-earnings-results.html.
In other news, CEO David P. Schenkein sold 80,000 shares of the stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $70.14, for a total value of $5,611,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David P. Schenkein sold 35,000 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $67.12, for a total transaction of $2,349,200.00. Following the completion of the sale, the chief executive officer now owns 35,000 shares in the company, valued at approximately $2,349,200. The disclosure for this sale can be found here. Insiders sold 170,762 shares of company stock worth $11,630,086 in the last quarter. Company insiders own 10.55% of the company’s stock.
A number of equities research analysts have commented on the stock. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $83.00 target price (up previously from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. J P Morgan Chase & Co reissued a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Royal Bank Of Canada initiated coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective for the company. SunTrust Banks, Inc. reissued a “buy” rating and set a $80.00 price objective (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Finally, Leerink Swann raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $50.00 to $80.00 in a research report on Wednesday, August 2nd. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $75.20.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.